Lars T. Van Der Veen

Utrecht, UT 3584CH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Journal: Molecular oncology

Published: September 01, 2025

Lipid-dependent growth of Malassezia spp. in defined medium with single fatty acids.

Lipid-dependent growth of Malassezia spp. in defined medium with single fatty acids.

Journal: FEMS yeast research

Published: May 22, 2025

Exploring germline variants in genes associated with inborn errors of immunity and inherited bone marrow failure syndromes in pediatric hematological malignancies.

Exploring germline variants in genes associated with inborn errors of immunity and inherited bone marrow failure syndromes in pediatric hematological malignancies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 09, 2025

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.

Journal: Haematologica

Published: December 12, 2024

Developing a translational research framework for MDD: combining biomolecular mechanisms with a spiraling risk factor model.

Developing a translational research framework for MDD: combining biomolecular mechanisms with a spiraling risk factor model.

Journal: Frontiers in psychiatry

Published: July 12, 2024

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Journal: International journal of toxicology

Published: September 05, 2023

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Journal: Molecular cancer therapeutics

Published: August 10, 2023

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.

Journal: Translational oncology

Published: June 11, 2023

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 26, 2023

A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs.

A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPs.

Journal: Cell genomics

Published: March 16, 2023

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort.

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort.

Journal: Journal of clinical immunology

Published: February 03, 2023

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Journal: Cancer research communications

Published: November 22, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026